查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930140

全球凝血因子市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的分析、未来预测（2026-2034）

Coagulation Factors Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

凝血因子市场成长驱动因子

全球凝血因子市场正经历强劲成长，这主要得益于出血性疾病的增加、血浆衍生疗法的进步以及主要市场参与者研发活动的扩大。根据 Fortune Business Insights 预测，该市场规模预计在 2025 年达到 68.9 亿美元，并在 2026 年成长至 74.3 亿美元。到 2034 年，该市场预计将达到 146.1 亿美元，2026 年至 2034 年的复合年增长率 (CAGR) 为 8.81%。

预计到 2025 年，北美将占市场主导地位，市占率高达 58.17%，这得益于其强大的血浆采集基础设施和先进疗法的广泛应用。

市场驱动因素

出血性疾病发生率上升

遗传性出血性疾病（例如血友病A、血友病B和血管性血友病）盛行率的上升是市场成长的关键驱动因素。根据美国疾病管制与预防中心 (CDC) 统计，美国约有33,000名男性患有血友病，而血管性血友病影响约1%的人口。患者数量的增加显着推动了对血浆衍生凝血因子浓缩物的需求。

创伤与事故发生率上升

全球事故和创伤病例的增加也促进了市场扩张。例如，根据印度公路运输和公路部的一份报告，2022年印度将发生超过461,312起道路交通事故，这将促使急诊和重症监护环境中对凝血因子的需求增加。

市场限制因子

严格的监理架构

由于对血浆采集、处理和分销的严格要求，凝血因子市场面临挑战。美国食品药物管理局 (FDA) 等监管机构根据 "公共卫生服务法" 和 "联邦食品、药品和化妆品法" 强制要求严格遵守相关规定，这可能会延迟审批并使製造商的运作复杂化。

市场机会

研发投入的增加

研发投入的增加正在创造新的成长机会。血浆分离设施的扩建和下一代疗法的开发正在增强市场前景。 2022年12月，CSL Behring在澳洲开设了一家新的血浆分离工厂，以支持血友病和免疫系统疾病的治疗，巩固了该市场的长期成长潜力。

市场趋势

创新长效疗法的推出

长效凝血因子、先进的血浆分离技术以及标靶给药系统的推出是关键的市场趋势。此外，人工智慧 (AI) 和物联网 (IoT) 技术的整合正在提高营运效率、供应链管理和患者参与度，从而促进市场扩张。

市场挑战

高昂的初始投资和治疗成本

血浆衍生产品生产设施需要大量资金，复杂的加工技术仍然是一项重大挑战。部分地区有限的保险覆盖范围和高昂的治疗成本阻碍了其普及，尤其是在新兴市场，影响了整体市场渗透率。

细分市场分析

依类型划分，VIII因子细分市场占最大市场占有率，这主要得益于A型血友病的高发生率。根据美国血友病联盟（2025年）统计，全球有超过110万人患有A型血友病。

依应用领域划分，血液学细分市场推动了市场成长，这主要归功于止血技术的进步以及血液相关疾病发病率的上升。

依终端使用者划分，医院和诊所占了大部分市场占有率，这主要得益于患者入院人数的增加以及医疗服务提供者与製造商之间的合作。

区域分析

预计到2025年，北美地区的市场收入将达到40.1亿美元，主要得益于血浆采集活动的增加和强有力的监管支持。

欧洲占第二大市场占有率，主要得益于血浆分离设施的扩张和策略性举措。联盟。

由于产能扩张和价格合理的血浆疗法，预计亚太地区在预测期内将实现强劲增长。

由于医疗基础设施的改善和公众意识的提高，预计拉丁美洲、中东和非洲地区将保持稳定成长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 出血性疾病的流行病学
  • 主要公司的新产品发布
  • 关键产业趋势：併购、业务合作等
  • 关税的影响市场

第五章 全球凝血因子市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依类型划分
    • 凝血因子IX
    • 凝血因子VIII
    • 凝血酶原复合物浓缩物
    • 纤维蛋白原浓缩物
    • 其他
  • 市场分析、洞察与预测：依应用划分
    • 免疫和神经系统疾病
    • 血液系统疾病
    • 重症监护
    • 其他
  • 市场分析、洞察与预测：依最终用户划分
    • 医院和诊所
    • 临床实验室
    • 其他
  • 市场分析、洞察与预测：依区域
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美凝血因子市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲凝血因子市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 其他欧洲国家

第八章 亚太地区凝血因子市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲凝血因子市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲凝血因子市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会（GCC）国家/地区
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • CSL
    • Takeda Pharmaceutical Company Limited
    • Kedrion S.p.A.
    • Octapharma AG
    • LFB
    • Bayer AG
Product Code: FBI112621

Growth Factors of coagulation factors Market

The global coagulation factors market is witnessing robust growth, driven by the increasing prevalence of bleeding disorders, advancements in plasma-derived therapies, and expanding research and development activities by key market players. According to Fortune Business Insights, the market was valued at USD 6.89 billion in 2025 and is projected to grow to USD 7.43 billion in 2026. By 2034, the market is expected to reach USD 14.61 billion, registering a compound annual growth rate (CAGR) of 8.81% from 2026 to 2034.

In 2025, North America dominated the market with a 58.17% share, supported by strong plasma collection infrastructure and advanced treatment availability.

Market Drivers

Rising Incidence of Bleeding Disorders

The growing prevalence of hereditary bleeding disorders such as hemophilia A, hemophilia B, and von Willebrand disease is a major factor driving market growth. According to the Centers for Disease Control & Prevention (CDC), approximately 33,000 males in the U.S. live with hemophilia, while von Willebrand disease affects nearly 1% of the population. The rising patient pool has significantly increased demand for plasma-derived coagulation products.

Increasing Trauma and Accident Cases

The rising number of accidents and trauma cases globally is further contributing to market expansion. For instance, India recorded over 461,312 road accidents in 2022, as reported by the Ministry of Road Transport and Highways, leading to increased demand for coagulation factors in emergency and critical care settings.

Market Restraints

Stringent Regulatory Frameworks

The coagulation factors market faces challenges due to stringent regulatory requirements governing plasma collection, processing, and distribution. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) enforce strict compliance under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act, which can delay approvals and increase operational complexity for manufacturers.

Market Opportunities

Growing Investments in Research and Development

Increasing investments in research and development are creating new growth opportunities. Expansion of plasma fractionation facilities and development of next-generation therapies are strengthening market prospects. In December 2022, CSL Behring opened a new plasma fractionation facility in Australia to support treatments for hemophilia and immune disorders, reinforcing long-term market growth potential.

Market Trends

Introduction of Innovative and Long-Acting Therapies

The launch of longer-acting coagulation factors, advanced plasma fractionation technologies, and targeted delivery systems is a key market trend. Additionally, integration of artificial intelligence (AI) and Internet of Things (IoT) technologies is improving operational efficiency, supply chain management, and patient engagement, contributing to market expansion.

Market Challenges

High Initial Investment and Treatment Costs

High capital requirements for plasma-derived manufacturing facilities and complex processing technologies remain a significant challenge. Limited reimbursement coverage in some regions and high therapy costs restrict broader adoption, particularly in emerging markets, thereby affecting overall market penetration.

Segmentation Analysis

By type, the Factor VIII segment held the largest market share, driven by the high prevalence of hemophilia A. According to the Hemophilia Federation of America (2025), more than 1.1 million individuals worldwide suffer from hemophilia A.

By application, the hematology segment dominated due to advancements in hemostasis technologies and rising cases of blood-related disorders.

By end user, hospitals and clinics accounted for the majority share, supported by higher patient admissions and collaboration between healthcare providers and manufacturers.

Regional Insights

North America generated USD 4.01 billion in revenue in 2025, driven by rising plasma collection activities and strong regulatory support.

Europe held the second-largest share due to expansion of plasma fractionation facilities and strategic partnerships.

Asia Pacific is projected to witness strong growth during the forecast period, supported by capacity expansion and affordable plasma-based therapies.

Latin America and the Middle East & Africa are expected to grow steadily with improving healthcare infrastructure and rising awareness.

Competitive Landscape

The market is moderately consolidated, with leading players such as CSL, Takeda Pharmaceutical Company, Kedrion S.p.A., and Octapharma AG focusing on capacity expansion, product innovation, and strategic collaborations. Continuous FDA approvals and new facility investments are strengthening their global market presence.

Conclusion

In conclusion, the global coagulation factors market is set for significant growth, expanding from USD 6.89 billion in 2025 to USD 14.61 billion by 2034. Rising prevalence of bleeding disorders, technological advancements, and increased investments in plasma-derived therapies are key growth drivers. Although regulatory complexities and high costs remain challenges, ongoing innovation, facility expansion, and strong demand across developed and emerging regions are expected to sustain long-term market growth during the forecast period.

Segmentation By Type

  • Factor IX
  • Factor VIII
  • Prothrombin Complex Concentrates
  • Fibrinogen Concentrates
  • Others

By Application

  • Immunology & Neurology
  • Hematology
  • Critical Care
  • Others

By End User

  • Hospitals & Clinics
  • Clinical Research Laboratories
  • Others

By Geography

  • North America (By Type, Application, End User, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Application, End User, and Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Application, End User, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of the Asia Pacific
  • Latin America (By Type, Application, End User, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Application, End User, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Epidemiology of Bleeding Disorders
  • 4.2. New Product Launches, By Key Players
  • 4.3. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
  • 4.4. Impact of Tariff on the Market

5. Global Coagulation Factors Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Factor IX
    • 5.1.2. Factor VIII
    • 5.1.3. Prothrombin Complex Concentrates
    • 5.1.4. Fibrinogen Concentrates
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Immunology & Neurology
    • 5.2.2. Hematology
    • 5.2.3. Critical Care
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospitals & Clinics
    • 5.3.2. Clinical Research Laboratories
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Coagulation Factors Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Factor IX
    • 6.1.2. Factor VIII
    • 6.1.3. Prothrombin Complex Concentrates
    • 6.1.4. Fibrinogen Concentrates
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Immunology & Neurology
    • 6.2.2. Hematology
    • 6.2.3. Critical Care
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospitals & Clinics
    • 6.3.2. Clinical Research Laboratories
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Coagulation Factors Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Factor IX
    • 7.1.2. Factor VIII
    • 7.1.3. Prothrombin Complex Concentrates
    • 7.1.4. Fibrinogen Concentrates
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Immunology & Neurology
    • 7.2.2. Hematology
    • 7.2.3. Critical Care
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospitals & Clinics
    • 7.3.2. Clinical Research Laboratories
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Coagulation Factors Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Factor IX
    • 8.1.2. Factor VIII
    • 8.1.3. Prothrombin Complex Concentrates
    • 8.1.4. Fibrinogen Concentrates
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Immunology & Neurology
    • 8.2.2. Hematology
    • 8.2.3. Critical Care
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospitals & Clinics
    • 8.3.2. Clinical Research Laboratories
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Coagulation Factors Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Factor IX
    • 9.1.2. Factor VIII
    • 9.1.3. Prothrombin Complex Concentrates
    • 9.1.4. Fibrinogen Concentrates
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Immunology & Neurology
    • 9.2.2. Hematology
    • 9.2.3. Critical Care
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospitals & Clinics
    • 9.3.2. Clinical Research Laboratories
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Coagulation Factors Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Factor IX
    • 10.1.2. Factor VIII
    • 10.1.3. Prothrombin Complex Concentrates
    • 10.1.4. Fibrinogen Concentrates
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Immunology & Neurology
    • 10.2.2. Hematology
    • 10.2.3. Critical Care
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Hospitals & Clinics
    • 10.3.2. Clinical Research Laboratories
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. CSL
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Takeda Pharmaceutical Company Limited
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Kedrion S.p.A.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Octapharma AG
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. LFB
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Bayer AG
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Coagulation Factors Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Coagulation Factors Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 3: Global Coagulation Factors Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 4: Global Coagulation Factors Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Coagulation Factors Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 6: North America Coagulation Factors Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 7: North America Coagulation Factors Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 8: North America Coagulation Factors Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Coagulation Factors Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 10: Europe Coagulation Factors Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 11: Europe Coagulation Factors Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 12: Europe Coagulation Factors Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Coagulation Factors Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Asia Pacific Coagulation Factors Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 15: Asia Pacific Coagulation Factors Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 16: Asia Pacific Coagulation Factors Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Coagulation Factors Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 18: Latin America Coagulation Factors Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 19: Latin America Coagulation Factors Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 20: Latin America Coagulation Factors Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Coagulation Factors Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Middle East & Africa Coagulation Factors Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 23: Middle East & Africa Coagulation Factors Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 24: Middle East & Africa Coagulation Factors Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Coagulation Factors Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Coagulation Factors Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Coagulation Factors Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Coagulation Factors Market Value Share (%), by End User, 2025 & 2034
  • Figure 5: Global Coagulation Factors Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Coagulation Factors Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America Coagulation Factors Market Value Share (%), by Type, 2025
  • Figure 8: North America Coagulation Factors Market Value (USD billion), by Application, 2025 & 2034
  • Figure 9: North America Coagulation Factors Market Value Share (%), by Application, 2025
  • Figure 10: North America Coagulation Factors Market Value (USD billion), by End User, 2025 & 2034
  • Figure 11: North America Coagulation Factors Market Value Share (%), by End User, 2025
  • Figure 12: North America Coagulation Factors Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Coagulation Factors Market Value Share (%), By Country, 2025
  • Figure 14: Europe Coagulation Factors Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe Coagulation Factors Market Value Share (%), by Type, 2025
  • Figure 16: Europe Coagulation Factors Market Value (USD billion), by Application, 2025 & 2034
  • Figure 17: Europe Coagulation Factors Market Value Share (%), by Application, 2025
  • Figure 18: Europe Coagulation Factors Market Value (USD billion), by End User, 2025 & 2034
  • Figure 19: Europe Coagulation Factors Market Value Share (%), by End User, 2025
  • Figure 20: Europe Coagulation Factors Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Coagulation Factors Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Coagulation Factors Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific Coagulation Factors Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific Coagulation Factors Market Value (USD billion), by Application, 2025 & 2034
  • Figure 25: Asia Pacific Coagulation Factors Market Value Share (%), by Application, 2025
  • Figure 26: Asia Pacific Coagulation Factors Market Value (USD billion), by End User, 2025 & 2034
  • Figure 27: Asia Pacific Coagulation Factors Market Value Share (%), by End User, 2025
  • Figure 28: Asia Pacific Coagulation Factors Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Coagulation Factors Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Coagulation Factors Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Latin America Coagulation Factors Market Value Share (%), by Type, 2025
  • Figure 32: Latin America Coagulation Factors Market Value (USD billion), by Application, 2025 & 2034
  • Figure 33: Latin America Coagulation Factors Market Value Share (%), by Application, 2025
  • Figure 34: Latin America Coagulation Factors Market Value (USD billion), by End User, 2025 & 2034
  • Figure 35: Latin America Coagulation Factors Market Value Share (%), by End User, 2025
  • Figure 36: Latin America Coagulation Factors Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Coagulation Factors Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Coagulation Factors Market Value (USD billion), by Type, 2025 & 2034
  • Figure 39: Middle East & Africa Coagulation Factors Market Value Share (%), by Type, 2025
  • Figure 40: Middle East & Africa Coagulation Factors Market Value (USD billion), by Application, 2025 & 2034
  • Figure 41: Middle East & Africa Coagulation Factors Market Value Share (%), by Application, 2025
  • Figure 42: Middle East & Africa Coagulation Factors Market Value (USD billion), by End User, 2025 & 2034
  • Figure 43: Middle East & Africa Coagulation Factors Market Value Share (%), by End User, 2025
  • Figure 44: Middle East & Africa Coagulation Factors Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Coagulation Factors Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Coagulation Factors Market Share (%), By Company, 2025